CSP
INMB icon

Cary Street Partners’s INmune Bio INMB Stock Holding History

Cary Street Partners’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,917
Closed -$21.7K – 1008
2025
Q4 		$21.7K Hold
13,917
– – ﹤0.01% 958
2025
Q3 		$28.8K Buy
+13,917
New +$31.9K ﹤0.01% 900

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cary Street Partners's INMB Position: Q1 2026 in Review

Cary Street Partners sold out of INmune Bio (INMB) in Q1 2026, closing a stake of 13,917 shares — an estimated $21.7K sold.

Cary Street Partners first reported a position in INMB in Q3 2025 and held it in 2 quarters. The position peaked at $28.8K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Cary Street Partners reported no remaining INmune Bio position as of Q1 2026 after selling out during the quarter.
  • Cary Street Partners sold 13,917 INmune Bio shares in Q1 2026, an estimated $21.7K.
  • Cary Street Partners first reported a position in INmune Bio in Q3 2025 and held it in 2 quarters.
  • Cary Street Partners's INmune Bio position peaked at $28.8K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Cary Street Partners's 13F filing for Q1 2026, filed 29 Apr 2026.